Navigation Links
'New' estrogen receptor found to be key player in tamoxifen resistance
Date:10/29/2008

Washington, D.C. Researchers at Georgetown University Medical Center have discovered a novel way in which breast cancer cells become resistant to tamoxifen, the world's largest-selling breast cancer prevention and treatment drug. They say the findings could provide a way to identify tamoxifen users who are no longer benefiting from the drug, allowing doctors to try another therapy option sooner.

In the November 1 issue of the journal Cancer Research, the researchers show that breast cancer cells that are resistant to tamoxifen display few of the "alpha" estrogen receptors that the drug is designed to bind on to and inhibit, but many more "gamma" estrogen-related receptors, which tamoxifen seems to activate. These two receptors are not closely related they are more like distant cousins than siblings, researchers say, adding that understanding how these gamma estrogen-related receptors work may eventually help in designing new, more effective drugs targeting these receptors.

In fact, they track how, as resistance develops over time, breast cancer cells gradually lose the alpha receptors while gaining the estrogen-related receptor gamma subtype.

The study offers two new insights, according to lead author Rebecca Riggins, Ph.D., a research assistant professor of oncology at GUMC's Lombardi Comprehensive Cancer Center.

One is a clearer understanding of the importance of the gamma estrogen-related receptor in breast cancer. "Until now, this receptor has not been viewed to be of much importance in any type of breast cancer," Riggins says. "All that was known is that there were more of these receptors in breast cancer than in normal breast tissue, we hadn't gone much further than that."

A second important insight is that the discovery could help explain why invasive lobular carcinoma the sub-type of breast cancer in which these findings were made may not respond as well to tamoxifen as perhaps other subtypes do, she says.

"It is unclear whether tamoxifen is very effective in this cancer, and has been a point of debate among clinicians," Riggins says. "This study is a good first step toward clarifying the role that tamoxifen resistance apparently plays in treatment of invasive lobular cancer."

Invasive lobular carcinoma, which accounts for 15 percent of newly diagnosed invasive breast cancers diagnosed each year, appear under the microscope as long, very thin tumors actually a single stream of cancer cells that line up in a row. That makes them much harder to diagnose than the more common cancer type, invasive ductal carcinoma, in which tumors form more discrete lumps.

But what the researchers found in invasive lobular carcinomas the specific cancer they studied - may also be true of tamoxifen resistance in other cancer types," she said "No one has looked for gamma estrogen-related receptors in tamoxifen resistance in invasive ductal carcinoma."

In addition to its use as a cancer preventive, tamoxifen is approved to treat both early and advanced breast cancer that is estrogen-receptor positive. (Estrogen-receptor positive cancer means that estrogen is the primary fuel that promotes cancer development and growth.) Tamoxifen binds to the estrogen receptors (alpha) that stud tumors and other breast tissue, not allowing estrogen to latch on and turn on a program of growth inside the cells. But it is estimated that 30 to 50 percent of breast cancer patients eventually become resistant to tamoxifen.

"The magnitude of this health issue is huge. More than 178,000 women will be diagnosed this year with invasive breast cancer, and 70 percent of them will have estrogen receptor-positive tumors," Riggins says. "It is clear that we need to understand why this resistance occurs."

"This is a very nice story of tamoxifen resistance in a somewhat under-investigated group of breast cancers," says the study's senior investigator, Robert Clarke, Ph.D., professor of oncology, physiology and biophysics and director of GUMC's Biomedical Graduate Research Organization. "It identifies a new player and shows some of its downstream signaling and how this affects responsiveness to tamoxifen in these breast cancers."

The findings came about after the research team developed the first cell culture model of tamoxifen-resistant, invasive lobular carcinoma. To do this, they took cells of this subtype and exposed them to low amounts of tamoxifen and allowed the cells to adapt to the agent. The researchers slowly increased the tamoxifen to match the dosage that a woman taking the drug would be exposed, and during this 10-month process, watched the cells develop resistance to the drug.

"Initially the cells were sensitive to tamoxifen, but as the dose increased, the sensitive cells died off, and the tumor repopulated itself with resistant cells," Riggins says.

During the experiment, the investigators measured gene expression, and were able to track higher and higher expression of the gamma estrogen-related receptor subtype.

"Clearly, the gamma estrogen-related receptors, which have a role in cell metabolism, are stimulating cancer growth, and it is possible that tamoxifen is activating this receptor, " Riggins says.

If alpha estrogen receptors can be used as a drug target, then perhaps the gamma estrogen-related receptor subtype can as well, she adds.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related biology news :

1. New, more direct pathways from outside the cell-to-cell nuclei discovered
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. New molecular regulators of hyperthyroidism and goiter
4. Newly created cancer stem cells could aid breast cancer research
5. Adding up renewable energy
6. Unravelling new complexity in the genome
7. New study warns limited carbon market puts 20 percent of tropical forest at risk
8. New study examines how rearing environment can alter navigation
9. News tips from the Journal of Neuroscience
10. Dominant cholesterol-metabolism ideas challenged by new research
11. Researchers identify proteins involved in new neurodegenerative syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
(Date:3/9/2017)... MELBOURNE , Australia , March ... clinical study data at the prestigious World Lung Imaging ... Dr. Andreas Fouras , was invited to deliver ... and pulmonary medicine. This globally recognised event brings together ... and share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... 2017 Cousins Properties (NYSE: CUZ ) ... companies, has signed a 10-year, approximately 125,000 square-foot lease at ... located in the Westshore submarket of Tampa, FL. ... has chosen Corporate Center for their new location in ... and chief executive officer of Cousins Properties. "Amgen is a ...
(Date:3/27/2017)... March 27, 2017  Perthera,s Chief Bioinformatics Officer and ... Subha Madhavan , Ph.D., will be speaking at the ... On Monday, March 27, 2017, she will be speaking ... Usable for Research and Care" (from 10:30 a.m. – ... she will be a participant in the "Making Precision ...
(Date:3/27/2017)... March 27, 2017  Trovagene, Inc. (NASDAQ: TROV), a ... Executive Officer, Bill Welch , will be presenting ... at 9:00 AM EDT at the Essex House in ... and Chief Scientific Officer, Mark Erlander , Ph.D., ... the conference.   The presentation will be webcast ...
(Date:3/24/2017)... ROCKVILLE, Md. , March 24, 2017  Infectex ... Fund (MBVF), today announced positive results of a Phase ... drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... by scientists at Sequella, Inc. ( USA ... A total of 140 patients were enrolled ...
Breaking Biology Technology: